Larimar Therapeutics Inc (LRMR)

Jan 23, 2025, 4:05 PM EST - 7 days ago

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia

Jan 3, 2025, 5:49 PM EST - 27 days ago

Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better

Dec 17, 2024, 1:39 PM EST - 6 weeks ago

What's Going On With Larimar Therapeutics Stock On Tuesday?

Dec 16, 2024, 12:17 PM EST - 6 weeks ago

Why Is Larimar Therapeutics Stock Trading Lower On Monday?

Dec 16, 2024, 7:00 AM EST - 6 weeks ago

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

Oct 30, 2024, 7:00 AM EDT - 3 months ago

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Oct 16, 2024, 2:59 PM EDT - 3 months ago

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock

Oct 6, 2024, 9:28 PM EDT - 4 months ago

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Sep 19, 2024, 7:00 AM EDT - 4 months ago

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

May 31, 2024, 4:11 PM EDT - 8 months ago

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

May 30, 2024, 4:05 PM EDT - 8 months ago

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia

May 20, 2024, 4:05 PM EDT - 9 months ago

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia

May 9, 2024, 7:00 AM EDT - 9 months ago

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

Mar 14, 2024, 4:05 PM EDT - 11 months ago

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

Mar 11, 2024, 4:05 PM EDT - 11 months ago

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia

Mar 6, 2024, 4:05 PM EST - 11 months ago

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Feb 16, 2024, 4:20 PM EST - 1 year ago

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Feb 14, 2024, 6:15 AM EST - 1 year ago

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

Feb 13, 2024, 4:18 PM EST - 1 year ago

Larimar Therapeutics Announces Proposed Underwritten Public Offering

Feb 12, 2024, 7:00 AM EST - 1 year ago

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

Nov 14, 2023, 7:00 AM EST - 1 year ago

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Nov 1, 2023, 4:05 PM EDT - 1 year ago

Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference

Oct 3, 2023, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

Aug 31, 2023, 4:05 PM EDT - 1 year ago

Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Aug 2, 2023, 6:02 AM EDT - 1 year ago

Larimar: Friedreich's Ataxia Drug With Significant Potential

Jul 25, 2023, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial

Jul 17, 2023, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

Jun 21, 2023, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Set to Join Russell 3000® Index

May 15, 2023, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial's 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich's Ataxia and First Quarter 2023 Financial Results

Mar 28, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days

Mar 14, 2023, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results

Feb 7, 2023, 4:05 PM EST - 2 years ago

Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer

Nov 21, 2022, 4:05 PM EST - 2 years ago

Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference

Nov 10, 2022, 7:00 AM EST - 2 years ago

Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results

Nov 7, 2022, 4:05 PM EST - 2 years ago

Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day

Oct 20, 2022, 8:00 AM EDT - 2 years ago

Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601

Oct 19, 2022, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research

Sep 26, 2022, 9:59 AM EDT - 2 years ago

MDA Breakout Stocks Week 39 - September 2022: Short-Term Picks To Give You An Edge

AAPL AMGN CAT CELH CLFD CVX DOW

Sep 16, 2022, 1:00 PM EDT - 2 years ago

Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares

Sep 14, 2022, 7:04 AM EDT - 2 years ago

Larimar Therapeutics Announces $70 Million Underwritten Offering

Sep 14, 2022, 7:01 AM EDT - 2 years ago

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich's Ataxia Patients

Aug 11, 2022, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results

Jul 28, 2022, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders

Jun 28, 2022, 8:00 AM EDT - 2 years ago

Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts

Jun 2, 2022, 8:00 AM EDT - 2 years ago

Larimar Therapeutics Announces Upcoming Scientific Conference Presentations

May 19, 2022, 8:00 AM EDT - 2 years ago

Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson's Disease and Movement Disorders Congress

May 12, 2022, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results

Mar 25, 2022, 7:00 AM EDT - 3 years ago

Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results